Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
plans a Q3 resubmission with a six-month review and is targeting approval in Q1 2027 while seeking an accelerated review. Anaphylm is a needle-free sublingual epinephrine film that showed faster absorption in company studies (12-minute Tmax vs ~20 minutes for an autoinjector) and is pitched as highly portable to address adherence issues versus autoinjectors that still hold 90% of the market. Ending 2025 with about $121 million in cash, management says the company has a runway to complete CRL remediation and maintain commercial readiness, with potential additional funding from an RTW credit line, out-licensing, or other deal options. Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive Therapeutics (NASDAQ:AQST) executives outlined the company's near-term regulatory plans and longer-term platform strategy during a presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference, with most of the discussion centered on Anaphylm,
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action LawsuitBusiness Wire
- Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Aquestive Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of May 4, 2026GlobeNewswire
- INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsPR Newswire
- Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
AQST
Earnings
- 3/4/26 - Miss
AQST
Sec Filings
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- 3/4/26 - Form 8-K
- AQST's page on the SEC website